Use of cDNA microarrays to estimate gene modulation profiles induced by zoledronic acid treatment in androgen-resistant prostate cancer cell line (PC3)

Published: June 8, 2009
Abstract Views: 139
PDF: 135
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The LNCaP and the PC3 cells are widely used as models for prostate cancer. Aminobisphosphonates have clearly demonstrated to inhibit proliferation and induce apoptosis in these cells by interfering with the mevalonate pathway. The types and pattern of downstream genes modulated by zoledronic acid (ZA) treatment are unknown. We used a cDNA microarray platform to analyse the genetic modulation induced by ZA in the PC3 prostate cancer cell line.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Santini, D., Vincenzi, B., Rosolowski, M., Altucci, L., Campioni, M., Loeffler, M., Baldi, A., & Tonini, G. (2009). Use of cDNA microarrays to estimate gene modulation profiles induced by zoledronic acid treatment in androgen-resistant prostate cancer cell line (PC3). Hematology Meeting Reports (formerly Haematologica Reports), 2(3). https://doi.org/10.4081/hmr.v2i3.365